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ABSTRACT: Neutralizing antibodies (NA) inherently 
present in pooled plasma collected at commercial 
abattoirs may provide some protection against potential 
porcine circovirus type 2 (PCV2) infectivity of plasma. 
Moreover, these NA may also contribute to the biosafety 
of spray-dried porcine plasma (SDPP). The objective of 
the study was to characterize and quantify the PCV2 
antibody neutralizing capacity in pooled liquid porcine 
plasma and SDPP samples collected from industrial 
spray-drying facilities located in the Southeast and 
Midwest regions of the United States and the Northeast 
region of Spain. In the United States, PCV2 NA was 
determined in 1 sample of pooled liquid plasma from 
commercial spray-drying plants in the Southeast and 
1 from the Midwest region. Obtained results were 
compared with those of a plasma sample from a PCV2 
vaccinated sow and 1 from a PCV2 antibody negative 
sow. In Spain, 15 pooled liquid porcine plasma samples 
and 10 SDPP samples were collected at a commercial 
spray-drying plant total and NA against PCV2 were 
determined. Results with pooled liquid porcine plasma 
from commercial spray-drying facilities in the United 
States indicated that NA titers against PCV2 in these 
samples (log2 8.33 ± 0.41 and 9.0 ± 0.0) were similar 
or greater than the plasma from the PCV2-vaccinated 
sow (log2 6.33 ± 0.41). The analysis of U.S. samples 
indicated that liquid plasma diluted to 1:256 (10–2.41) 
was able to neutralize between 100 to 200 PCV2 
virus particles or about 4 logs10 median tissue culture 
infective dose (TCID50) per milliliter. Similarly, samples 
from the Spanish pooled liquid plasma and the SDPP 
samples indicated an increased amount of NA activity 
against PCV2. Specifi cally, a dilution of 10–2.47 ± 0.33 of 
plasma was able to inactivate 100 PCV2 virus particles; 
therefore, the inactivation capacity of commercial 
liquid plasma was greater than 104 TCID50/mL. The 
calculated 90% reduction in infected cells because of 
NA in pooled plasma samples (log2 8.2 ± 0.38) was less 
(P < 0.05) than in its concentrate form of SDPP (mean, 
log2 10.2 ± 0.85). In conclusion, PCV2 NA contained 
in liquid pooled plasma from market pigs was detected 
at greater concentrations than that from a vaccinated 
sow and that after spray-drying biological neutralizing 
activity was conserved, which implies that the inherent 
NA in liquid plasma may have an important role in the 
biosafety of commercially produced SDPP.
Key words: biosafety, neutralizing antibodies, porcine 
circovirus type 2, spray dried porcine plasma, virus neutralization
© 2013 American Society of Animal Science. All rights reserved.  J. Anim. Sci. 2013.91:2192–2198
 doi:10.2527/jas2012-5705
INTRODUCTION
Spray-dried porcine plasma (SDPP) is well 
recognized as a key ingredient in diets for weaned 
pigs (Nelssen et al., 1999) because it promotes 
improvements in growth and feed intake and reduces 
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postweaning diarrhea (Coffey and Cromwell, 2001; 
Torrallardona, 2010). Porcine circovirus type 2 (PCV2) 
is a small circular, nonenveloped, single-stranded 
DNA virus (Tischer et al., 1982) found in most swine 
worldwide (Allan and Ellis, 2000; Zhou et al., 2006) and 
is very resistant to physical and chemical inactivation 
procedures (Royer et al., 2001; Martin et al., 2008) 
and dry heat treatment (O’Dea et al., 2008). Therefore, 
there are concerns that PCV2 may not be completely 
inactivated in commercial SDPP. Patterson et al. (2010) 
demonstrated PCV2 seroconversion in pigs after 
oral gavage of laboratory produced SDPP that was 
derived from a pig experimentally infected with PCV2. 
Analytical results of commercial SDPP reported the 
presence of PCV2 DNA copies (Pujols et al., 2011b; 
Shen et al., 2011). However, recent studies demonstrated 
that commercial SDPP containing PCV2 DNA copies 
did not transmit PCV2 when fed to healthy pigs for long 
periods (Pujols et al., 2008; Shen et al., 2011).
The failure to demonstrate PCV2 transmission by 
feeding commercial SDPP has been partially attributed 
to the more robust thermodynamics of commercial 
spray driers that result in rapid dehydration and 
involves a minimum heat treatment of 80ºC throughout 
its substance (Polo et al, 2005; Pujols et al., 2008; 
Shen et al., 2011). In addition, the high prevalence of 
neutralizing antibodies (NA) in pooled liquid plasma 
may also contribute to the lack of transmission (Pujols 
et al, 2011a). Pooling of NA is a recognized safety step 
in production of human plasma products (Williams and 
Khan, 2010). Therefore, our objectives were to evaluate 
the activity of NA against PCV2 in pooled liquid plasma 
and to estimate their potential contribution to the 
biosafety of commercial SDPP.
MATERIALS AND METHODS
Study 1
Sample Collection Procedures and Storage. The 
commercial pooled liquid plasma were obtained from 
federally inspected slaughterhouses that follows USDA 
guidelines related with animal care at the time of slaughter. 
Blood collection and processing at the slaughterhouse 
does not involve any modifi cation of the slaughter, not in 
the method nor in time. Two commercial pooled liquid raw 
plasma samples (8% solids) from 2 federally inspected 
abattoirs located in the Southeast and the Midwest areas 
of the United States were collected in 50-mL conical 
tubes from tankers at the spray-drying facility. During 
slaughter, plasma is typically collected from multiple pigs, 
pooled, and held in tanks at each abattoir before transport 
in insulated tankers to spray-drying facilities. Each tanker 
contains plasma from approximately 9,000 to 10,000 
pigs. Plasma samples were immediately frozen after 
collection and stored at –20°C. Samples were shipped 
frozen overnight on wet ice to the Veterinary Medicine 
Laboratory at Iowa State University (Ames, IA) where 
they were immediately stored at –80°C until analysis.
One PCV2 antibody positive plasma (PP) sample 
obtained from a sow vaccinated against PCV2 (1 mL 
intramuscularly; Ingelvac CircoFLEX; Boehringer 
Ingelheim Vetmedica, Inc., Ingelheim, Germany) 140 d 
before collection and 1 negative control (NC) plasma 
sample from a nonvaccinated sow that was negative for 
PCV2 antibodies as determined by ELISA (Nawagitgul 
et al., 2002) and PCV2 DNA as determined by real-time 
PCR (Opriessnig et al., 2003) were also used in this study. 
All samples were diluted at 1:10 with modifi ed eagle 
medium (MEM) and 1% antibiotic and antimycotic 
(AB/AM) mixture and heat inactivated at 56°C for 
30 min before making the serial 2-fold dilutions. The 
diluted plasma samples were then centrifuged at 3,200 × 
g for 10 min at 4°C and supernatants obtained were used 
for the different analytical determinations. All samples 
were analyzed in triplicate.
Porcine Circovirus Type 2 Real-Time Quantitative 
PCR and ELISA. Presence, amount, and genotype of 
PCV2 DNA in the plasma samples were determined by 
real-time PCR assays (Shen et al., 2011). The presence 
of anti-PCV2 antibodies was determined using an open 
reading frame 2-based PCV2 IgG ELISA (Nawagitgul 
et al., 2002). Pooled liquid plasma samples were diluted 
in normal saline solution to constant solids of 8% before 
testing. The sample-to-positive (S:P) ratio was calculated 
by dividing the sample optical density at 450 nm by the 
positive control optical density, and samples with an S:P 
ratio of 0.2 or greater were considered positive.
Neutralizing Antibody Testing Procedure. Two-
fold serial dilutions, consisting of 100 μL plasma in 
MEM with 1% AB/AM on a 96-well cell culture plate 
with a starting dilution of 4 and then adding 100 μL of 
PCV2 (PCV2a ISUVDL 98-15237) inoculum at a rate of 
100 fl uorescent focus units to all wells, were made. After 
incubation in 5% CO2 at 37°C for 30 min and 1, 3, or 6 
h, 100 μL of PK15 cell suspension in MEM with 10% 
fetal bovine serum (FBS) and 1% AB/AM mixture were 
added to each well, and the plates were incubated in 5% 
CO2 at 37°C for an additional 48 h. The cell monolayer 
was then treated with 300 mM D-glucosamine (Sigma 
Chemical Co., St. Louis, MO) prepared in a MEM 
suspension of 25 μL/well for 20 min. After treatment, 
the cell monolayer was washed once with MEM and 
replenished with 200 μL of fresh MEM supplemented 
with 10% FBS and 1% AB/AM mixture and incubated 
for another 16 h. After the additional 16 h of incubation, 
the cell monolayer was fi xed in cold 80% acetone (50 μL/
well). Fifty microliters of PCV2-monoclonal antibody 
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(Rural Technologies, Inc., Brooking, SD) diluted at 
1:1,000 with PBS was added to all wells and incubated for 
30 min at 37°C. The plates were washed with PBS, and 
then fl uorescein isothiocyanate anti-mouse conjugate 
(KPL, Inc., Gaithersburg, MD) diluted at 1:100 in PBS 
was added to all wells (50 μL/well). The plates were then 
incubated for an additional 30 min at 37ºC. All plates 
were washed 3 times with PBS and dried. Plates were 
read using a fl uorescent microscope at a magnifi cation 
of 100 or 40x. Cells with nuclear or cytoplasmatic 
fl uorescent staining or both were recorded as infected. 
The percentage of virus neutralization at each dilution 
was calculated according to this formula: [1 – (number 
of positive cells of each serum dilution/mean number 
of positive cells in the negative control cells)] × 100. 
The NA titer was expressed as the reciprocal of the last 
dilution in which a given sample reduced the number of 
PCV2-infected cells by 90%.
Study 2
Sample Collection Procedures and Storage. 
Fifteen pooled liquid plasma samples were collected in 
20 mL conical tubes during 5 consecutive d from the 
holding tank of liquid plasma at the Spanish commercial 
spray-drying facility. The plasma samples were 
collected each day at 3 different time intervals during 
the production cycle for adequate characterization 
of the daily production. Samples were taken from the 
plasma tank at the beginning, midpoint, and end of the 
daily production cycle. Like in the United States, the 
samples were collected from a tanker containing plasma 
from approximately 9,000 to 10,000 pigs. All plasma 
samples were immediately frozen after collection and 
stored at –25°C. Samples were transported frozen to 
the laboratory (Centre de Recerca en Sanitat Animal, 
Universitat Autònoma de Barcelona, Barcelona, Spain) 
where they were stored at –80°C until analyzed.
In addition, samples from 10 manufacturing batches 
of SDPP representing from 35,000 to 40,000 pigs per 
batch were analyzed for presence of total antibodies 
and NA against PCV2a and PCV2b. The dried samples 
were collected and tested independently from the 
liquid samples. These dried samples were previously 
solubilized in sterilized deionized water at a rate of 1:9 
before mixing with the virus particles.
Porcine Circovirus Type 2 Real-Time Quantitative 
PCR and Serology. Detection and amount of PCV2 
DNA genome present in the pooled liquid raw plasma 
and SDPP samples were determined by a real-time 
PCR assay (Olvera et al., 2004). The presence of total 
antibodies to PCV2 in the commercial pooled liquid 
porcine plasma samples and diluted dried samples were 
investigated by an immunoperoxidase monolayer assay 
(IPMA; Fort et al., 2007).
Neutralizing Antibody Testing Procedure. Fifty 
microliters of serum tested (either from the liquid plasma 
or from the diluted dried plasma) were serially diluted 
2-fold in 96-well plates from 1:20 to 1:20,480 in complete 
MEM (with 5% FBS, 100 mM L-glutamine, 100 U/mL of 
penicillin, 100 mg/mL streptomycin, and 3% nonessential 
amino acids). Fifty microliters at 200 median tissue 
culture infective dose (TCID50) of a PCV2a stock 
(Burgos strain 390/L8, known to react with antibodies 
elicited against PCV2b isolates; Kurtz et al., 2010) were 
added to each well. After 2 h of mixture incubation, 
20,000 freshly trypsinized PK-15 cells were added to 
each well and incubated for 72 h at 37ºC in 5% CO2. 
Cells were fi xed in absolute ethanol at –20ºC for 30 min. 
Infected cells were then revealed by IPMA technique 
(Fort et al., 2007). Plates were read using a microscope 
at 100x amplifi cation. Wells containing cells with nuclear, 
cytoplasmatic, or both staining patterns were recorded as 
infected and affected cells were individually counted. The 
percentage of virus seroneutralization (%SNT) at each 
dilution was calculated according to this formula: %SNT = 
[1 – (mean number of positive cells of 2 replicas of each 
serum dilution/mean number of positive cells in negative 
control wells)] × 100. To validate the plate, previous 
defi ned criteria were used (Fort et al., 2007), including 
positive and negative controls and back titration on virus 
inoculum. The NA titer was calculated as the reciprocal 
of the last dilution, in which a given serum sample was 
able to reduce the number of PCV2-infected cells by 90%. 
These values were designated as SNT90%.
Statistical Analyses
Results of NA titers were expressed as mean ± SD 
of the log2 of the reciprocal plasma dilution. Analysis 
of variance among different samples (U.S. samples) or 
sampling periods during the day or between days of the 
liquid plasma sample collection (Spanish samples) was 
performed using the ANOVA simple analysis (Statgraphics 
Centurion XV; StatPoint Technologies, Inc., Warrenton, 
VA). Statistical differences of means were determined using 
LSD as an all pairwise multiple comparison procedure. The 
t-student test was used to compare the values between liquid 
and dried plasma of the Spanish samples. Differences were 
considered signifi cant when P < 0.05.
RESULTS
Study 1
The anti-IgG PCV2 S:P ratios of the 2 pooled 
plasma samples collected from commercial spray-drying 
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facilities and the PP sample are summarized in Table 1. 
The NC samples did not contain measurable anti-PCV2 
IgG antibodies. Antibodies to PCV2b was identifi ed in 
both pooled commercial plasma samples (log10 5.37 – 
5.54 genomic copies per mL). The NC and PP samples 
did not contain PCV2 DNA.
Both commercial liquid plasma samples had NA 
titers greater than the positive control plasma sample 
from the PCV2 vaccinated sow (P < 0.05), indicating 
that pooled plasma samples from commercial abattoirs 
contained greater concentrations of NA against PCV2 than 
concentrations expected in vaccinated animals (Table 1). 
The NA titers for the NC sample were less than 2 log2 
(below the detection limit). Differences in respect to the 
incubation time between the plasma and the SNT90% titer 
were not statistically signifi cant although numerically the 
results obtained after 1 h of incubation were greatest.
Study 2
The total antibody titers against PCV2 in the liquid 
samples had an average of log2 12.79 ± 1.00 as measured 
by IPMA. The mean PCV2 genomic copies were log10 
4.84 ± 0.23/mL. The NA titers in these samples had an 
average SNT90% of PCV2 infected cells of log2 8.20 ± 
1.08 (Table 2). The correlation (r = 0.143) between total 
antibodies and NA in the liquid plasma was low.
No statistical differences between total or NA titers 
against PCV2 were observed during the 5 consecutive 
days tested. Also, no differences for total or NA titers 
were observed by sampling intervals (beginning, 
midpoint, and end) of the manufacturing process.
In the SDPP samples from Spain (Table 3), the average 
total antibody titers were 14.52 ± 0.26 log2 and 10.30 ± 
1.06 log2 for SNT90% NA. The correlation (r = 0.014) 
between total antibodies and NA was low but similar to 
liquid plasma. In SDPP samples, the mean PCV2 genomic 
copies/mL was log10 3.53 ± 0.20. Titers in SDPP were 
greater (P < 0.001) for both IPMA and NA compared with 
the values obtained from the liquid plasma.
DISCUSSION
Pooling plasma is a recognized safety step in 
the production of certain human plasma products 
(Solheim et al., 2000, 2006, 2008) because of 
successful neutralization of antigens in the presence of 
corresponding antibodies, especially for stable viruses 
that are diffi cult to inactivate by other methods (Solheim 
et al., 2008; Williams and Khan, 2010).
Although a single pig may not have antibodies 
to all pathogens present in the population, a batch of 
commercially produced SDPP is represented by the 
pooled plasma from approximately 6,000 to 10,000 pigs. 
Therefore, it is likely that this pooled plasma contains 
antibodies and NA against all pathogens circulating in 
the pig population at any point in time. Several authors 
(Pujols et al., 2011a; Shen et al., 2011) suggested that, 
in addition to the thermal dehydration by spray-drying 
liquid plasma, the inherent NA against specifi c viruses 
of concern in liquid plasma should contribute to the 
biosafety of commercial SDPP.
Dietary spray-dried plasma improves postweaning 
feed intake and growth of pigs (Coffey and Cromwell, 
Table 1. Porcine circovirus type 2 (PCV2) ELISA sample-
to-positive (S:P) ratios and virus neutralizing antibody (NA) 
titers at different times of in vitro exposure in commercial 
pooled liquid plasma samples from the Southeast and 
Midwest slaughter regions of the United States
Sample1
PCV2 ELISA 
S:P ratio
PCV2 NA by time2
30 min 1 h 3 h 6 h
NC 0.000 <2 <2 <2 <2
PP 0.784 5.3 ± 0.4 6.3 ± 0.4 5.7 ± 0.4 5.7 ± 0.4
Southeast 0.895 8.0 ± 0.0 8.3 ± 0.4 7.7 ± 0.4 7.7 ± 0.4
Midwest 0.758 8.0 ± 0.0 9.0 ± 0.0 8.0 ± 0.0 8.3 ± 0.4
1NC is the negative control plasma sample from a sow that was not 
vaccinated with PCV2 vaccine; PP is the positive control plasma sample from 
a sow that was vaccinated with PCV2 vaccine; Southeast is pooled liquid 
plasma from market pigs slaughtered at abattoirs located in the Southeast 
region of the United States; Midwest is pooled liquid plasma from market pigs 
slaughtered at abattoirs located in the Midwest region of the United States.
2The NA titers are expressed as the mean of log2 of the reciprocal of the 
serum dilution ± SEM able to reduce the virus replication by 90% over various 
incubation time intervals. Neutralizing antibody titers were determined by 
fl uorescence focus neutralization assay.
Table 2. Immunoperoxidase monolayer assay (IPMA) 
antibody titers to porcine circovirus type 2 (PCV2) and 
virus neutralizing antibody (NA) titers against PCV2 
at 90% of viral neutralization endpoint (SNT90%) in 
commercial pooled liquid porcine plasma samples collected 
by day of production and at different time intervals within 
day of production at a drying facility in Spain
Sample1 IPMA titers for PCV2 antibody2 PCV2 NA SNT90%3
d 1 12.0 ± 0.4 8.7 ± 1.5
d 2 12.3 ± 0.0 7.7 ± 0.8
d 3 13.0 ± 0.8 8.3 ± 0.4
d 4 13.7 ± 0.8 8.0 ± 0.7
d 5 13.0 ± 0.8 8.3 ± 0.4
Beginning 13.1 ± 0.6 7.6 ± 0.3
Middle 12.1 ± 0.2 8.2 ± 0.4
End 13.1 ± 0.6 8.8 ± 0.7
1Pooled liquid plasma samples were collected at the Spanish drying facility 
for 5 consecutive d at the beginning, middle (after half of the production run), 
and end of the production run (just before the plasma deposit was empty).
2Immunoperoxidase monolayer assay antibody titers to PCV2 (expressed 
as mean of log2 of the reciprocal of the serum dilution ± SEM) for each 
production day and within production day sampling period.
3Neutralizing antibody at 90% of viral neutralization end point (expressed 
as mean of log2 of the reciprocal of the serum dilution ± SEM) for each 
production day and within production day sampling period.
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2001; Van Dijk et al., 2001; Torrallardona, 2010) as 
well as productive measures for lactating sows and 
their progeny (Crenshaw et al., 2007). Based on current 
evidence, the use of SDPP in animal feed is considered 
safe and there are numerous steps in the manufacturing 
process of commercial SDPP that contribute to the 
biosafety of this functional protein ingredient. Only 
blood from healthy pigs that have passed antemortem 
inspection by veterinary competent authorities and 
approved as fi t for slaughter for human consumption is 
collected for commercially produced SDPP. Avoidance 
of collecting plasma from clinically affected pigs 
decreases the risk of potential pathogen transmission. 
Other steps such as spray drying have demonstrated their 
effi cacy as a pasteurization-like process to eliminate 
different bacteria and viruses (Pujols et al., 2008). 
Studies have shown the effectiveness of spray drying 
to inactivate bacterial coliforms (Polo et al., 2002) as 
well as viruses of importance to the swine industry 
such as porcine reproductive and respiratory syndrome 
virus, pseudorabies virus (Polo et al., 2005), or swine 
vesicular disease virus (Pujols et al., 2007). Design 
and confi guration of the spray-drying process affects 
microbial survival; therefore, it may not be appropriate to 
extrapolate and interpret data obtained from a laboratory 
spray drier to that of a commercial spray dryer (Thybo 
et al., 2008). As a consequence, it is not recommended 
to conduct safety studies of heat-resistant viruses, 
such as porcine parvovirus (PPV) or PCV2, based on 
material produced by a laboratory spray drier. In fact, 
these machines have less capability of viral inactivation 
compared with commercial spray driers because of 
various factors, such as droplet size, shear forces, drying 
temperatures, and dwell time of particles inside the drier 
(Shen et al., 2011). For these heat resistant viruses, it is 
recommended to conduct safety studies by feeding naïve 
pigs with diets containing commercial SDPP at greater 
inclusion levels and for a 3 to 4 times longer duration 
than typical commercial conditions. Several studies 
have indicated that SDPP does not transmit either PPV 
or PCV2 (Polo et al., 2005; Pujols et al., 2008, 2011a; 
Shen et al., 2011), which are 2 of the most heat and 
chemically resistant swine viruses.
Neutralizing antibodies seem to be essential to 
clear PCV2 infection in pigs, and low titers of PCV2 
NA have been linked to the occurrence of postweaning 
multisystemic wasting syndrome (PMWS), which is 
associated with PCV2 infectivity (Meerts et al., 2006; 
Fort et al., 2007). Also, PCV2 vaccination induces PCV2 
NA in piglets and may prevent detectable PCV2 viremia 
after challenge (Fort et al., 2008). Thus, available 
data indicate that PCV2 virus particles are neutralized 
by PCV2 NA and development of PMWS is reduced 
or prevented. Because both vaccinated and naturally 
infected PCV2 pigs usually have greater NA titers than 
NC, it is expected that their presence in commercially 
collected pooled liquid blood or plasma would neutralize 
PCV2 virus particles that might be present in the blood 
from subclinically infected pigs.
The present results with pooled liquid porcine plasma 
collected from commercial abattoirs in the United States 
indicated that PCV2 NA titers in these samples were 
similar or greater than titers detected from a single PCV2 
vaccinated sow 140 d after vaccination. This result 
indicates that both PCV2 infection and extensive PCV2 
vaccination protocols used in the United States contribute 
to the high presence of PCV2 NA detected in slaughter 
pigs. Similarly, positive titers of PCV2 NA were detected 
in samples of pooled liquid porcine plasma collected 
from a commercial spray-drying plant in Spain, which 
is consistent with the results in grower–fi nisher pigs 
selected from 34 different farms located in northeastern 
Spain (Fort et al., 2007). Also, the presence of positive 
titers of total antibodies against PCV2 were detected in 
278 samples of SDPP from daily batches collected over 
a 14 mo period (November 2009 to December 2010) at 
Spanish manufacturing plants (Polo et al., 2011). The 
Spanish SDPP samples came from 25 abattoirs, which 
represented >60% of the total Spanish pig production.
The results of the Spanish samples indicated a 
consistent presence of total and NA against PCV2 with 
minimal day-to-day or within-day variation in both liquid 
and spray-dried porcine plasma. In addition, results 
indicated that total PCV2 antibody titers in SDPP also 
had low variability as demonstrated by the small SD of 
the 10 manufactured lots tested. This is in agreement with 
Table 3. Immunoperoxidase monolayer assay (IPMA) 
antibody titers against PCV2 at 90% of viral neutralization 
endpoint (SNT90%) in commercial spray-dried porcine 
plasma samples from Spain
Lot number1 IPMA PCV2 antibody titers2 PCV2 NA SNT90%3
Y024542 14.3 ± 0.0 10.0 ± 0.6
Y024652 14.8 ± 0.7 9.0 ± 0.0
Y024912 14.3 ± 0.0 9.7 ± 0.3
Y025022 14.3 ± 0.0 10.3 ± 0.3
Y025132 14.3 ± 0.0 10.0 ± 0.6
Y025242 14.8 ± 0.7 9.0 ± 0.0
Y025352 14.8 ± 0.7 11.7 ± 0.3
Y025462 14.8 ± 0.7 10.7 ± 0.3
Y025612 14.3 ± 0.0 11.0 ± 0.0
Y025722 14.3 ± 0.0 10.7 ± 0.3
1Ten consecutive manufacturing lots of spray-dried porcine plasma 
samples were collected at a drying facility in Spain.
2Immunoperoxidase monolayer assay antibody titers to PCV2 (expressed 
as mean of log2 of the reciprocal of the serum dilution ± SEM) for the 
different manufacturing lots.
3Neutralizing antibody at 90% of viral neutralization end point (expressed 
as mean of log2 of the reciprocal of the serum dilution ± SEM able to reduce 
the virus replication by 90%) for the different manufacturing lots.
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Borg et al. (2002), who reported that samples of spray-
dried plasma collected during a whole year of production 
from different manufacturing plants located in the United 
States, Argentina, and Spain contained a consistent and 
signifi cant amount of antibody titers against a variety 
of specifi c pathogenic bacteria (Escherichia coli K88, 
E. coli K99, Salmonella typhimurium, and Clostridium 
botulinum). Recently, Shen et al. (2011) reported 
that all 116 liquid, concentrated, and spray-dried U.S. 
commercial plasma samples contained positive titers 
of PCV2 antibodies. These data are consistent with 
the ubiquitous nature of PCV2 (Allan and Ellis, 2000; 
Walker et al., 2000; Zhou et al., 2006).
The present study with pooled plasma samples from 
the United States indicates that liquid plasma diluted 
1:256 (10–2.41) was able to inactivate between 100 to 200 
TCID50 of infectious PCV2 virus particles, indicating that 
PCV2 NA in pooled plasma from commercial abattoirs 
could inactivate around 104 TCID50/mL of PCV2 virus 
particles. In the instance of the liquid plasma from Spain, 
it was found that a dilution of 10–2.47 ± 0.33 of plasma 
was able to inactivate 100 TCID50 of PCV2 virus 
particles. Therefore, the inactivation capacity of liquid 
pooled plasma collected from commercial slaughter pigs 
is greater than 104 TCID50/mL of virus. The inherent 
NA in liquid plasma can be recognized as an effective 
safety step according to the established guidelines for 
virus validation studies for human plasma (EMEA, 1996, 
2001; Millipore, 2002). These guidelines defi ne a unit 
operation biosafety step as effective, ineffective, or 
moderately effective. Effective steps provide a reduction 
factor of at least 4 logs10 and are unaffected by small 
perturbations in process variables. Ineffective steps 
provide a reduction factor of 1 or less, and moderately 
effective steps fall between these 2 extremes. Therefore, 
the results of the present studies indicate that inherent NA 
in liquid pooled plasma can be considered an effective 
biosafety step in the manufacturing process of SDPP.
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